EDINBURGH, Scotland  — TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. The partnership will perform pharmacokinetic analysis using its AlloCell solution in the ACHIEVE clinical trial.
The ACHIEVE clinical trial is an adaptive, open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma delta T cell therapy for patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
CareDx is a leading precision medicine company focused on discovering, developing, and commercializing healthcare solutions for transplant patients and caregivers. CareDx’s AlloCell test, a sensitive solution for pharmacokinetic monitoring of allogeneic immune and stem cell therapies, will be used to evaluate the expansion and persistence of TCB008 in patients enrolled in the ACHIEVE trial.
It is expected that these expansion and persistence data will provide an understanding of the duration and effect of TCB008 Gamma Delta T-Cells in reconstituting the immune system of acute myeloid leukemia patients enrolled in the ACHIEVE trial.
“Our partnership with CareDx is a significant milestone,” said Alison Bracchi, Executive Vice President of Clinical Operations at TC BioPharm. “The collaboration is pivotal to the development and optimization of TCB008 as a therapy for acute myeloid leukemia and other blood cancers.”
“We are thrilled to continue to progress the science of allogeneic cell therapy for patients battling acute myeloid leukemia,” said Marica Grskovic, PhD, CareDx Chief Strategy Officer. “This partnership builds upon our growth strategy to expand into hematology oncology with pharmacokinetic and monitoring assays for patients undergoing cell therapy.”
